Redmile Group LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Redmile Group LLC
CRD #143606
SEC #801-67747
CIK #0001425738
AUM 4,701.1 M (2026-06-30)
Employees 30 (50% Investors, 0% Brokers)
Fees
Minimum
Phone415-489-9980
Address900 Larkspur Landing Circle
Larkspur, CA 94939
Source [IAPD] [EDGAR] [Website]
Total AUM ($B)
151296302005201220192027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5 - Fees and Compensation

Management Fees. As compensation for investment supervisory services rendered to the Funds,
the Firm receives from each such Fund a management fee (each, a “Management Fee”). The
Management Fee is typically calculated based on the net assets of a limited partner’s capital
accounts or a shareholder’s common shares, as applicable, before accrual of any applicable
incentive allocation or fee or based on the aggregate capital commitments of limited partners. The
precise amount of, and the manner and calculation of, the Management Fees for each Fund are
established by the Firm and are set forth in such Fund’s Organizational Documents. The
Management Fees and other fees and distributions described herein are generally subject to
modification, waiver or reduction by the Firm in its sole discretion, both voluntarily and on a
negotiated basis with selected investors via side letter and other arrangements, which, to the extent
permitted by applicable law, may not be disclosed to other investors in the same Fund.
Specifically, the applicable General Partner and the Firm, each in their sole discretion, have in the
past agreed, and may in the future agree, to waive or reduce the Management Fee charged to
investors that are (i) those who provide strategic and/or technical advice to a General Partner, the
Firm or their affiliates; (ii) General Partner members, Firm employees or affiliates of such General
Partner or the Firm, and (iii) investors in one or more Funds who have a certain collective minimum
capital commitment/investment. The fee structures described herein may be modified from time
to time. Fees may differ from one Fund to another, as well as among investors in the same Fund.

Management Fees vary Fund by Fund and may be payable monthly, quarterly, or semi-annually
in advance. Upon termination of an Advisory Agreement, Management Fees that have been
prepaid will be returned on a prorated basis.

Furthermore, certain General Partners have entered into and may, in the future, enter into a side
letter or similar agreement with an investor of any of the Funds, without the approval of any other
investor, which has the effect of establishing rights under, or altering or supplementing the terms
of a Fund’s Organizational Documents.

Firm Expenses. To the extent provided in the Organizational Documents, and except as described
herein as a Fund or portfolio company expense, the General Partner and/or the Firm will bear
certain expenses and costs associated with the performance of its services, including the
compensation and expenses of certain of its employees and general overhead expenses including,

                                                   Part 2A of ADV: Redmile Group, LLC Brochure

rent, utilities and expenses for administrative, clerical and related support services, except to the
extent that legal, accounting or other specialized consulting, advisory or professional services are
required that the General Partners, the Firm or an affiliate thereof would not normally be expected
to render with their own professional staff (the costs of which services will be borne by the
applicable Fund as detailed below).

Fund Expenses. Subject to the Organizational Documents of the Funds, the Funds will generally
bear organizational expenses, including expenses of their initial organization and the offering
and/or sale of common shares or interests including, but not limited to, out-of-pocket costs incurred
by or on behalf of the applicable General Partner or their respective affiliates in connection with
the marketing, formation, and organization of the Funds and the General Partners, as applicable,
including legal, accounting, travel, meeting, printing and other fees and expenses incident thereto
as well as, with respect to certain Funds, private placement fees, finder’s fees or other similar fees
paid to an independent third party in connection with the sale of interests. With respect to certain
other Funds, the aforementioned expenses may be subject to a cap. Generally, the Funds will bear
fees and expenses associated with the ongoing offering and/or sale of common shares or interests,
including updating, supplementing and distributing of such amended Organizational Documents
and other relevant materials.

Each Fund will also bear all other expenses, fees, charges, taxes and liabilities relating to it to the
extent not borne by its portfolio companies or portfolio investments including, but not limited to,
the Management Fee or any other fees payable to the General Partners or the Firm, the registrar
and transfer agent and the administrator; directors fees; all costs and expenses incurred in
connection with the purchase, holding, monitoring, sale, proposed sale or transmittal of any Fund
investment or of Fund assets (whether or not any such purchase or sale is consummated); research
expenses; interest on and fees and expenses arising out of all margin accounts, indebtedness and
other permitted borrowing made by such Fund; real property or personal property taxes on
investments, including documentary, recording, stamp and transfer taxes; investment expenses
such as brokerage fees or commissions, trading and support services including payments to
assisting brokers, investment related travel expenses; direct fees and expenses such as legal fees
and other due diligence expenses incurred related to the analysis, purchase, sale or exchange of
securities or other investments (whether or not ultimately consummated) (including Co-
Investments (as defined below), Designated Investments and Special Investments); expenses
incurred in connection with the investigation, prosecution or defense of any claims by or against a
Fund, including claims by or against a governmental authority; proxy voting service fees;
consulting fees relating to investments or proposed investments; consulting fees paid to consultants
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7 - Types of Clients

The Firm serves as investment manager to the Funds. Investment advice is provided directly to
the Funds (subject to the direction and control of the General Partner of each such Fund, if
applicable) and not individually to investors in such Fund.
Sector Form 13F Holdings Value ($B)
Scholar Rock Holding Corp 0.4
Krystal Biotech Inc 0.2
Stoke Therapeutics Inc 0.1
Immunome Inc 0.1
Nurix Therapeutics Inc 0.1
Annexon Inc 0.1
ADC Therapeutics Sa 0.1
RegenxBio Inc 0.0
Shattuck Labs Inc 0.0
Beam Therapeutics Inc 0.0
View All
Holdings by Sector ($B)
10.08.06.04.02.00.02011201620212027
Type Form D Funds Date Sold AUM
PE RM Special Holdings 9 LLC 2026-03-01 3.5 M
HF Redmile Strategic Long Only Trading Sub Ltd [2022-08-15] 498.6 M 162.0 M
Filed 2026-03-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $286,876 · Net Assets Decline to Disclose
HF Redmile Strategic Trading Sub Ltd [2022-08-15] 498.6 M 169.7 M
Filed 2026-03-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $286,876 · Net Assets Decline to Disclose
VC Redmile Growth Investments I LP [2022-02-09] 122.0 M 137.0 M
Filed 2022-07-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE RM Special Holdings 8 LLC 2022-02-09 0.4 M
HF Redco II Master Fund LP [2021-03-31] 31.4 M 1,555.9 M
Filed 2021-05-26 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE Redmile Biopharma Investments III LP [2021-02-26] 500.2 M 1,133.8 M
Filed 2021-01-04 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE RM Special Holdings 4 LLC 2021-02-26
HF Redco I LP [2020-08-27] 187.5 M 40.6 M
Filed 2020-05-26 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
VC Redmile Biopharma Investments II LP [2019-03-29] 675.4 M 661.0 M
Offered $675,420,000 · Filed 2020-03-05 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Commission $7,300,000 · Revenue Decline to Disclose
HF Redmile Capital Offshore II Master Fund Ltd 2019-03-29 738.2 M
HF Redmile Capital Offshore Master Fund Ltd [2019-03-29] 2,120.8 M 206.2 M
Filed 2026-03-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Commission $4,447,150 · Net Assets Decline to Disclose
HF P Redmile Ltd 2018-03-01 30.6 M
VC RAF LP 2018-03-01 230.8 M
HF Redmile Strategic Master Fund LP [2018-03-01] 498.6 M 976.3 M
Filed 2026-03-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $286,876 · Net Assets Decline to Disclose
HF Redmile Capital Offshore Fund ERISA Ltd [2016-02-25] 302.2 M 0.7 M
Filed 2025-03-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Commission $215,988 · Net Assets Decline to Disclose
VC Redmile Biopharma Investments I LP [2015-12-15] 218.3 M 144.9 M
Offered $218,270,000 · Filed 2018-07-27 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Duration One year or less · Commission $103,226 · Revenue Decline to Disclose
HF Redmile Long Only Master Fund LP 2015-12-15 81.7 M
VC Redmile Private Investments II LP [2015-12-15] 131.2 M 7.0 M
Offered $131,247,606 · Filed 2017-12-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration More than one year · Revenue Decline to Disclose
VC Redmile Private Investments I Affiliates LP [2015-03-31] 28.7 M 3.5 M
Offered $28,735,000 · Filed 2017-03-02 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose
VC Redmile Private Investments I LP [2013-10-30] 4.7 M
Offered $150,000,000 · Filed 2013-05-20 (D) · Exemption 506, 3(c), 3(c)(1), 3(c)(7) · Remaining $150,000,000 · Duration More than one year · Revenue Decline to Disclose
HF Redmile Capital Fund LP [2012-03-30] 1,132.1 M 171.9 M
Filed 2026-03-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $6,460,401 · Net Assets Decline to Disclose
HF Redmile Capital Offshore Fund II Ltd 2012-03-30 564.7 M
HF Redmile Capital Offshore Fund Ltd [2012-03-30] 2,120.8 M 1,344.0 M
Filed 2026-03-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Commission $4,447,150 · Net Assets Decline to Disclose
HF Redmile Special Opportunities Fund Ltd [2012-03-30] 431.5 M 58.5 M
Filed 2026-03-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 26 4.7
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 26 4.7
By Discretionary
Discretionary 26 4.7
Non-Discretionary 0 0.0
Total 26 4.7
By Non-United States Persons
Non-United States Persons 3.2
United States Persons 1.5
Total 26 4.7
Form D Directors Role # Filings # Firms 2011 - 2026
Ronan Guilfoyle Director 358 108
Roger Hanson Director 255 86
Vijayabalan Murugesu Director 129 26
Philip Hughes Director 87 17
Mike Lee Executive Officer, Promoter 21 3
Gerard van Hamel Platerink Director, Promoter 19 2
Jeremy Green Director, Executive Officer, Promoter 16 2
Amrit Nagpal Executive Officer, Promoter 11 2
Redmile Group LLC Director, Executive Officer, Promoter 10 2
Rob Faulkner Promoter 3 2
View All
EDGAR Form CIK 2011 - 2026
13F-HR [0001425738]
3 [0001425738]
4 [0001425738]
SC 13D [0001425738]
SC 13G [0001425738]
Form 13D/13G Filer Form 13D/13G Subject Filed
Redmile Group LLC Agomab Therapeutics NV [2026-05-15]
Redmile Group LLC Atara Biotherapeutics Inc [2025-05-23]
Redmile Group LLC Silence Therapeutics PLC [2025-02-14]
Redmile Group LLC Pliant Therapeutics Inc [2024-11-14]
Redmile Group LLC RegenxBio Inc [2023-11-17]
Redmile Group LLC ALX Oncology Holdings Inc [2023-10-16]
Redmile Group LLC Immunome Inc [2023-10-12]
Redmile Group LLC Neoleukin Therapeutics Inc [2023-07-27]
Redmile Group LLC Akero Therapeutics Inc [2023-02-14]
Redmile Group LLC Ayala Pharmaceuticals Inc [2023-02-08]
View All
Firm Profile (Form ADV)
Discretionary AUM$0.1B
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI5493007T2I6TUUZ37I60
Form 3/4/5 Subject 2011 - 2026
Redmile Group LLC
Green Jeremy
Fate Therapeutics Inc
RedCo II Master Fund LP
ADC Therapeutics SA
IGM Biosciences Inc
Shattuck Labs Inc
Atara Biotherapeutics Inc
Malo Holdings Corp
Redmile Private Investments II LP
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
2025-10-27 Buy 3,846,153 $3.90 14,999,997
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
2025-10-27 Buy 3,846,153 $3.90 14,999,997
IGM Biosciences Inc IGMS
Non-Voting Common Stock · derivative
2025-08-14 Disposed to issuer 7,199,325
IGM Biosciences Inc IGMS
Pre-Funded Warrants to Purchase Common Stock · derivative
2025-08-14 Disposed to issuer 667,666
IGM Biosciences Inc IGMS
Common Stock
2025-08-14 Disposed to issuer 2,964,843
Shattuck Labs Inc STTK
Stock Option (Right to Buy) · derivative
2025-07-14 Grant 33,150 $0.00
IGM Biosciences Inc IGMS
Common Stock
2025-06-30 Grant 828 $0.00
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
2025-06-11 Buy 15,734,267 $3.43 53,968,536
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
2025-06-11 Buy 12,465,234 $3.43 42,755,753
Fate Therapeutics Inc FATE
Stock Option (Right to Buy) · derivative
2025-05-29 Grant 55,000 $0.00
IGM Biosciences Inc IGMS
Common Stock
2025-03-31 Grant 828 $0.00
IGM Biosciences Inc IGMS
Common Stock
2024-12-31 Grant 1,734 $0.00
Fate Therapeutics Inc FATE
Common Stock
2024-12-20 Other 1,084,936 $1.68 1,822,692
Fate Therapeutics Inc FATE
Class A Convertible Preferred Stock · derivative
2024-12-20 Other 116,261 $8.40 976,592
Fate Therapeutics Inc FATE
Common Stock
2024-12-20 Buy 397,964 $1.68 668,580
Fate Therapeutics Inc FATE
Cash-settled Swaps · derivative
2024-12-20 Other 56,331 $1.68 94,636
Fate Therapeutics Inc FATE
Class A Convertible Preferred Stock · derivative
2024-12-20 Other 116,261 $8.40 976,592
Fate Therapeutics Inc FATE
Common Stock
2024-12-20 Other 1,084,936 $1.68 1,822,692
Fate Therapeutics Inc FATE
Common Stock
2024-12-20 Sell 341,633 $1.68 573,943
Fate Therapeutics Inc FATE
Class A Convertible Preferred Stock · derivative
2024-12-12 Conversion 6,022
showing 20 of 200 most recent transactions
Comparable Firms State AUM
Senator Investment Group LP
NY 4,923.6 M
Hill City Capital LP
MA 4,864.0 M
Kinetic Partners Management LP
FL 4,727.8 M
Washington Harbour Partners LP
VA 4,725.1 M
Clearwater Management Co Inc
MN 4,681.9 M
Shelter Growth Capital Partners LLC
CT 4,662.5 M
Caxton Associates USA LLC
NY 4,627.3 M
Corvex Management LP
NY 4,568.4 M
VR Adviser LLC
NY 4,495.4 M
Evanston Capital Management LLC
IL 4,490.6 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com